New drug TISA-818 shows promise for ARDS in early trial
NCT ID NCT07319351
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II study tested an injectable drug called TISA-818-Inj in 57 adults with acute respiratory distress syndrome (ARDS), a severe lung condition. Participants received either a low dose, a high dose, or a placebo for 14 days. The main goal was to check safety, with secondary goals looking at how long patients needed breathing support. Results may help decide if larger studies are warranted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TISA-818-Inj (an injectable drug)
What this could lead to
If successful, this could point toward a new treatment option for ARDS, potentially reducing time on ventilators and improving survival.
What could go wrong
This is a small, early-phase trial (57 patients) focused on safety, so results may not confirm effectiveness. The drug may not work better than placebo or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
China-Japan Friendship Hospital
Beijing, Beijing Municipality, 100029, China